The role of serum I-FABP concentration in assessment of small intestine mucosa among HIV-infected patients

Abstract

Objectives: The intestinal fatty acid binding protein (I-FABP) is a useful marker in the assessment of damages and inflammation to the small intestinal mucosa. We have investigated the influence of HIV infections and antiretroviral treatment on the small intestine mucosa aided by the evaluation of I-FABP concentration levels. Methods: We included in the study: 31 HIV-infected patients with antiretroviral therapy (ART) treatment (T), 32 HIVinfected patients not treated with ART (NT), and 18 healthy volunteers as a control group. The concentrations of I-FABP were measured in serum using a sandwich enzyme immunoassay kit: Human I-FABP. Results: The median level of I-FABP in the serum of HIV-infected patients was 2.10 ± 2.56 ng/mL and did not significantly differ between T and NT (2.32 ± 2.69 ng/mL vs. 1.89 ± 2.45 ng/mL). However, the I-FABP serum level was significantly higher in HIV-infected patients when compared to the group control (2.10 ± 2.56 ng/mL vs. 1.26 ± 1.18 ng/mL; P = 0.048). We recorded a correlation for treated HIV-infected patients between Viral load and I-FABP serum level (r =-0.66; P <0.05). Conclusions: Elevated serum I-FABP level in HIV-infected patients confirm that HIV causes damage to the intestinal mucosa. I-FAB is a useful marker in the assessment of intestinal damage in HIV-infected patients.